NANTONG CITY, China, May 14 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC:SNBP) (BULLETIN BOARD: SNBP) ("Sinobiopharma" or, the "Company") is pleased to announce that production of its flagship drug, Cisatracurium Besylate, increased by 350% in the first quarter of 2009 compared to production in the first quarter of 2008. In response to a sharp rise in orders, Sinobiopharma increased the total output of the skeletal muscle relaxant to 214,900 units in the first quarter of 2009, compared to 47,700 units for the same period in 2008. "We were able to achieve the dramatic rise in production despite the global economic crisis and challenges within the Chinese pharmaceutical industry," said Lequn Huang, Company President and CEO. "We anticipate that demand for our flagship product, and for our newly launched anti-hypertensive, Perindopril, will continue to grow. We also expect that this growth, and planned acquisitions in 2009, will drive a higher level of performance for Company this year." Sinobiopharma distributes Cisatracurium Besylate in 30 provinces and key major cities throughout China through sales partners and other sales networks. About Sinobiopharma Sinobiopharma Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs. FORWARD LOOKING STATEMENTS This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law. DATASOURCE: Sinobiopharma, Inc. CONTACT: Sinobiopharma, Inc., Investor Relations, 1-877-568-0188 Web Site: http://www.sinobiopharma.com/

Copyright